Protease-activated receptor 2 attenuates doxorubicin-induced apoptosis in colon cancer cells
- 22 November 2023
- journal article
- research article
- Published by Wiley in Journal of Cell Communication and Signaling
- Vol. 17 (4) , 1293-1307
Abstract
Drug resistance represents a major problem in cancer treatment. Doxorubicin (adriamycin) is an injectable DNA intercalating drug that halts cancer cell growth by inhibiting topoisomerase 2, but its long-term effectiveness is compromised by onset of resistance. This study demonstrates that expression of the PAR2 gene in human colon adenocarcinoma tissue samples was the highest among 32 different cancer types (n = 10,989), and higher in colon adenocarcinoma tissues (n = 331) than normal colon tissues (n = 308), revealing an association between PAR2 expression and human colon cancer. HT29 cells are a human colorectal adenocarcinoma cell line that is sensitive to the chemotherapeutic drug doxorubicin and also expresses PAR2. We find that PAR2 activation in HT29 cells, either by an endogenous protease agonist (trypsin) or an exogenous peptide agonist (2f-LIGRL-NH2), significantly reduces doxorubicin-induced cell death, reactive oxygen species production, caspase 3/7 activity and cleavage of caspase-8 and caspase-3. Moreover, PAR2-mediated MEK1/2-ERK1/2 pathway induced by 2f-LIGRL-NH2 leads to upregulated anti-apoptotic MCL-1 and Bcl-xL proteins that promote cellular survival. These findings suggest that activation of PAR2 compromises efficacy of doxorubicin in colon cancer. Further support for this conclusion came from experiments with human colon cancer HT29 cells, either with the PAR2 gene deleted or in the presence of a pharmacological antagonist of PAR2, which showed full restoration of all doxorubicin-mediated effects. Together, these findings reveal a strong link between PAR2 activation and signalling in human colon cancer cells and increased survival against doxorubicin-induced cell death. They support PAR2 antagonism as a possible new strategy for enhancing doxorubicin therapy. Graphical abstractKeywords
Funding Information
- NHMRC Investigator Leadership L3 Award (2009551)
- Australian Research Council Centre of Excellence (CE200100012)
This publication has 72 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancersNature, 2012
- Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors: Figure 1.Genes & Development, 2012
- Tissue factor–protease-activated receptor 2 signaling promotes diet-induced obesity and adipose inflammationNature Medicine, 2011
- Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancerOncogene, 2011
- Cathepsin S Elicits Itch and Signals via Protease-Activated ReceptorsJournal of Investigative Dermatology, 2010
- Dose- and time-dependent effects of doxorubicin on cytotoxicity, cell cycle and apoptotic cell death in human colon cancer cellsToxicology, 2010
- Colorectal cancer cells with the BRAFV600E mutation are addicted to the ERK1/2 pathway for growth factor-independent survival and repression of BIMOncogene, 2008
- Protease-Activated Receptor (PAR) 2, but not PAR1, Signaling Promotes the Development of Mammary Adenocarcinoma in Polyoma Middle T MiceCancer Research, 2008
- A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicinBiochemical Pharmacology, 1999